Goldman Sachs’s Ernexa Therapeutics ERNA Stock Holding History
Bought
Maintained
Sold
Other funds holding ERNA
DIG
Goldman Sachs's ERNA Position: Q2 2026 in Review
Goldman Sachs sold out of Ernexa Therapeutics (ERNA) in Q2 2026, closing a stake of 665 shares — an estimated $3.31K sold.
Goldman Sachs first reported a position in ERNA in Q2 2016 and held it in 12 quarters. The position peaked at $293K in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.
- Goldman Sachs reported no remaining Ernexa Therapeutics position as of Q2 2026 after selling out during the quarter.
- Goldman Sachs sold 665 Ernexa Therapeutics shares in Q2 2026, an estimated $3.31K.
- Goldman Sachs first reported a position in Ernexa Therapeutics in Q2 2016 and held it in 12 quarters.
- Goldman Sachs's Ernexa Therapeutics position peaked at $293K in Q4 2021.
- 9 funds tracked by Wall St. Rank held Ernexa Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.